NASDAQ: ENTX

Entera Bio Ltd.

Healthcare | Biotechnology

No licensed closing price on file for ENTX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2025)$0.25

Entera Bio Ltd. (NASDAQ: ENTX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:47 UTC.

What Entera Bio Ltd. does

Entera is a clinical-stage company developing oral tablet formats of peptides and protein therapies for chronic diseases currently treated with injections. The company's technology platform, called N-Tab, is designed to stabilize and help absorb large peptides through the gastrointestinal tract. Its lead program, EB613, is an oral form of teriparatide intended to treat osteoporosis as a bone-building therapy and references the established injectable drug Forteo as a comparator.

Summarized from Entera Bio Ltd.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	DEF 14A 2026-06-03
EPS (FY2025)	$0.25
Return on equity	-87.31%

Revenue, margins & earnings

Net income
Taxes & interest
Operating expenses
Cost of revenue
Net loss year

Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-08-07

2026-08-07DirectorStock Option (right to buy)Award33,368—
2026-08-07DirectorStock Option (right to buy)Award43,405—
2026-08-07DirectorStock Option (right to buy)Award50,000—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

Knoll Capital Management, LLC5,881,879$10.41M0.0%
BVF INC/IL2,425,000$4.29MNEW
Siren, L.L.C.736,457$1.30MNEW

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2023-06-07Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersHaya TaitelEstimatedSEC 8-K →
2022-07-18Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2022-06-17Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersPhillip SchwartzEstimatedSEC 8-K →

Company news

View all →

Entera Bio prices $275M private placement
Seeking Alpha Markets2026-07-27
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market
globenewswire.com2026-06-23POS
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
globenewswire.com2026-04-14

Questions this page answers

What does Entera Bio Ltd. do?

Entera is a clinical-stage company developing oral tablet formats of peptides and protein therapies for chronic diseases currently treated with injections.

When did ENTX last file with the SEC?

Entera Bio Ltd.'s most recent SEC filing on record is a DEF 14A filed 2026-06-03. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:47 UTC. This page is also available as JSON at /api/data?ticker=ENTX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ENTX and 5,000+ tickers.

Create a free account — keep ENTX

For your agent

GET /api/data?ticker=ENTX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt